Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.
作者： J Souglakos , J Philips , R Wang , S Marwah , M Silver
关键词: Metastasis 、 Pathology 、 Predictive value of tests 、 Medicine 、 Salvage therapy 、 KRAS 、 Oncology 、 Colorectal cancer 、 Cetuximab 、 Hazard ratio 、 Cancer 、 Internal medicine
摘要: We address the prognostic and predictive value of KRAS, PIK3CA BRAF mutations for clinical outcomes in response to active agents treatment metastatic colorectal cancer (mCRC). determined tumours from 168 patients treated mCRC at two institutions. All received 5-FU-based first-line chemotherapy outcome was analysed retrospectively. were present 62 (37%), 13 (8%) 26 (15%) cases, respectively. Multivariate analysis uncovered mutation as an independent factor decreased survival (hazard ratio (HR) 4.0, 95% confidence interval (CI) 2.1–7.6). In addition, with BRAF-mutant had significantly lower progression-free (PFS: HR CI 2.2–7.4) than those whose tumors that carried wild-type BRAF. Among 92 using cetuximab salvage therapy, KRAS associated lack (P=0.002) shorter PFS (P=0.09). (P=0.0005) (P=0.01) also predicted reduced therapy. These results underscore potential mutational profiling identify CRCs different natural histories or responses. The adverse significance should inform patient selection stratification trials.
nature.com
sci-hub.se 参考文章(26)
Wells A. Messersmith, Dennis J. Ahnen, Targeting EGFR in Colorectal Cancer The New England Journal of Medicine. ,vol. 359, pp. 1834- 1836 ,(2008) , 10.1056/NEJME0806778
C.-H. Huang, D. Mandelker, O. Schmidt-Kittler, Y. Samuels, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, S. B. Gabelli, L. M. Amzel, The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations Science. ,vol. 318, pp. 1744- 1748 ,(2007) , 10.1126/SCIENCE.1150799
Harith Rajagopalan, Alberto Bardelli, Christoph Lengauer, Kenneth W. Kinzler, Bert Vogelstein, Victor E. Velculescu, Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. ,vol. 418, pp. 934- 934 ,(2002) , 10.1038/418934A
Wade S. Samowitz, Carol Sweeney, Jennifer Herrick, Hans Albertsen, Theodore R. Levin, Maureen A. Murtaugh, Roger K. Wolff, Martha L. Slattery, Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers Cancer Research. ,vol. 65, pp. 6063- 6069 ,(2005) , 10.1158/0008-5472.CAN-05-0404
Bert Vogelstein, Kenneth W Kinzler, Cancer genes and the pathways they control. Nature Medicine. ,vol. 10, pp. 789- 799 ,(2004) , 10.1038/NM1087
L. D. Wood, D. W. Parsons, S. Jones, J. Lin, T. Sjoblom, R. J. Leary, D. Shen, S. M. Boca, T. Barber, J. Ptak, N. Silliman, S. Szabo, Z. Dezso, V. Ustyanksky, T. Nikolskaya, Y. Nikolsky, R. Karchin, P. A. Wilson, J. S. Kaminker, Z. Zhang, R. Croshaw, J. Willis, D. Dawson, M. Shipitsin, J. K. V. Willson, S. Sukumar, K. Polyak, B. H. Park, C. L. Pethiyagoda, P. V. K. Pant, D. G. Ballinger, A. B. Sparks, J. Hartigan, D. R. Smith, E. Suh, N. Papadopoulos, P. Buckhaults, S. D. Markowitz, G. Parmigiani, K. W. Kinzler, V. E. Velculescu, B. Vogelstein, Genomic landscapes of human breast and colorectal cancers Science. ,vol. 318, pp. 1108- 1113 ,(2008) , 10.1126/SCIENCE.1145720
Shunsuke Kato, Satoru Iida, Tetsuro Higuchi, Toshiaki Ishikawa, Yoko Takagi, Masamichi Yasuno, Masayuki Enomoto, Hiroyuki Uetake, Kenichi Sugihara, PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. International Journal of Cancer. ,vol. 121, pp. 1771- 1778 ,(2007) , 10.1002/IJC.22890
David B. Solit, Levi A. Garraway, Christine A. Pratilas, Ayana Sawai, Gad Getz, Andrea Basso, Qing Ye, Jose M. Lobo, Yuhong She, Iman Osman, Todd R. Golub, Judith Sebolt-Leopold, William R. Sellers, Neal Rosen, BRAF mutation predicts sensitivity to MEK inhibition Nature. ,vol. 439, pp. 358- 362 ,(2006) , 10.1038/NATURE04304
Suzanne Schubbert, Kevin Shannon, Gideon Bollag, Hyperactive Ras in developmental disorders and cancer Nature Reviews Cancer. ,vol. 7, pp. 295- 308 ,(2007) , 10.1038/NRC2109
Eric Van Cutsem, Marc Peeters, Salvatore Siena, Yves Humblet, Alain Hendlisz, Bart Neyns, Jean-Luc Canon, Jean-Luc Van Laethem, Joan Maurel, Gary Richardson, Michael Wolf, Rafael G. Amado, Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 25, pp. 1658- 1664 ,(2007) , 10.1200/JCO.2006.08.1620